VGTI Florida, founded in 2008, is a leader in biotechnology, with a focus on researching the human immune system's response to pathogens and cancer. Their efforts aim to prevent and treat infectious diseases, cancer, and enhance the immunity of the elderly. They have formed collaborations with both local and global partners to develop innovative vaccines and treatments for a range of conditions, including HIV/AIDS, breast and ovarian cancer, influenza, as well as emerging infectious diseases such as Yellow Fever, West Nile Virus, and Dengue Fever. The company received a notable $3.60M grant investment on 15 July 2013, with the National Institutes of Health being the contributing investor. This investment underscores the confidence in VGTI Florida's groundbreaking research and its potential impact on healthcare. The company's dedication to addressing critical health challenges through novel biotechnological advancements positions it as a noteworthy player in the field, making it an attractive prospect for venture capital investors seeking promising opportunities in biotechnology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $3.60M | 1 | National Institutes of Health | 15 Jul 2013 |
No recent news or press coverage available for VGTI Florida.
We care about your data, and we'd love to use cookies make your experience better.
